Tscan Therapeutics Inc (TCRX) Shares Plummet Below 1-Year High

Tscan Therapeutics Inc (NASDAQ: TCRX)’s stock price has gone decline by -10.11 in comparison to its previous close of 8.01, however, the company has experienced a -9.21% decrease in its stock price over the last five trading days. InvestorPlace reported 2024-03-17 that Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.

Is It Worth Investing in Tscan Therapeutics Inc (NASDAQ: TCRX) Right Now?

The 36-month beta value for TCRX is at 0.90. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The public float for TCRX is 36.44M, and currently, shorts hold a 0.52% of that float. The average trading volume for TCRX on April 03, 2024 was 173.28K shares.

TCRX’s Market Performance

The stock of Tscan Therapeutics Inc (TCRX) has seen a -9.21% decrease in the past week, with a 0.00% drop in the past month, and a 23.50% gain in the past quarter. The volatility ratio for the week is 9.70%, and the volatility levels for the past 30 days are at 8.18% for TCRX. The simple moving average for the past 20 days is -0.65% for TCRX’s stock, with a 67.60% simple moving average for the past 200 days.

Analysts’ Opinion of TCRX

Many brokerage firms have already submitted their reports for TCRX stocks, with Wedbush repeating the rating for TCRX by listing it as a “Outperform.” The predicted price for TCRX in the upcoming period, according to Wedbush is $8 based on the research report published on June 22, 2023 of the previous year 2023.

TCRX Trading at 11.76% from the 50-Day Moving Average

After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.00% of loss for the given period.

Volatility was left at 8.18%, however, over the last 30 days, the volatility rate increased by 9.70%, as shares surge +1.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.58% upper at present.

During the last 5 trading sessions, TCRX fell by -9.21%, which changed the moving average for the period of 200-days by +169.66% in comparison to the 20-day moving average, which settled at $7.25. In addition, Tscan Therapeutics Inc saw 23.50% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TCRX starting from BARBERICH TIMOTHY J, who purchase 317 shares at the price of $4.97 back on Dec 19 ’23. After this action, BARBERICH TIMOTHY J now owns 67,027 shares of Tscan Therapeutics Inc, valued at $1,575 using the latest closing price.

BARBERICH TIMOTHY J, the Director of Tscan Therapeutics Inc, purchase 28,830 shares at $4.89 during a trade that took place back on Dec 18 ’23, which means that BARBERICH TIMOTHY J is holding 66,710 shares at $140,881 based on the most recent closing price.

Stock Fundamentals for TCRX

Current profitability levels for the company are sitting at:

  • -4.44 for the present operating margin
  • 0.75 for the gross margin

The net margin for Tscan Therapeutics Inc stands at -4.28. The total capital return value is set at -0.39. Equity return is now at value -71.29, with -37.87 for asset returns.

Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.84. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -52.07.

Currently, EBITDA for the company is -88.1 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 12.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.51.


In conclusion, Tscan Therapeutics Inc (TCRX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts